Biognosys partners with SISCAPA in the USA
Schlieren/Washington D.C. - Biognosys has entered into a strategic partnership with SISCAPA Assay Technologies, a specialist in the area of protein quantification activities, for the US market. Through this partnership, Biognosys will be in a position to offer end-to-end solutions.
(CONNECT) Biognosys, a biotechnology firm from Schlieren in the canton of Zurich, Switzerland, is now working with SISCAPA Assay Technologies in the USA. According to a press release, the company from Washington, D.C. which specializes in highly sensitive protein quantification activities, has developed workflows based on mass spectrometry. The platform is said to allow researchers and physicians to perform precision measurements that are crucial for biomarker development and clinical diagnostics, as Biognosys writes in the press release.
This partnership will aim to offer end-to-end solutions, i.e., holistic concepts for the targeted quantification of proteins with high sensitivity. Within the framework of this collaboration, Biognosys will become the preferred service provider for delivering the immune enrichment technology developed by SISCAPA to biopharmaceutical customers, who will now have a single, reliable partner covering every step of the journey from biomarker discovery to clinical implementation.
“By integrating our strengths, we are enabling customers to accelerate biomarker development and confidently translate their discoveries into impactful clinical insights”, as Oliver Rinner, CEO and co-founder of Biognosys, states in the press release.
“By directly connecting our technologies, we can provide a seamless roadmap for understanding protein biomarkers, targets and drugs”, explains Leigh Anderson, CEO and founder of SISCAPA Assay Technologies.
Biognosys is a spin-off of the Swiss Federal Institute of Technology in Zurich (ETH) with its headquarters at the Bio-Technopark Schlieren-Zurich. ce/gba
